Seattle Genetics Careers in Seattle, WA

Seattle Genetics is a biotechnology company focused on developing and commercializing empowered antibody-based therapies for the treatment of cancer. We are leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, has been approved for two indications in more than 35 countries. To expand on the ADCETRIS opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME and ASG-15ME. Seattle Genetics’ ADC tech